Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
Launched by TAKESHI MORIMOTO · Apr 21, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective and safe aspirin is for patients with chronic coronary syndromes who are not eligible for surgery to improve their heart condition. Chronic coronary syndromes can cause chest pain and other heart-related symptoms due to narrowed arteries. The trial aims to see if taking aspirin can help these patients manage their condition better.
To participate in the study, candidates need to be adults with significant narrowing (at least 50%) in their heart arteries but who cannot have procedures like surgery to fix them. They should also be able to understand and give consent to participate. However, people with certain conditions, such as a history of heart attacks or strokes, or those currently on other blood-thinning medications, cannot join. Participants will likely receive regular check-ups and monitoring throughout the trial to ensure their safety and to evaluate how well aspirin is working for their heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization
- • Patients for whom consent can be obtained
- Exclusion Criteria:
- • Patients with history of acute coronary syndromes (ACS)
- • Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
- • Patients with left main trunk stenosis (≥50%)
- • Patients for whom aspirin administration is mandatory
- • Patients undergoing antithrombotic therapy other than aspirin
- • Patients with atrial fibrillation
- • Patients with history of stroke within six months
- • Patients scheduled for major surgical procedures that will require aspirin discontinuation
- • Patients with contraindication of aspirin
- • Patients expected to have a prognosis of 1 year or less due to comorbidities
- • Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization
- • Patients who are judged by attending physicians to be inappropriate to participate in this study
About Takeshi Morimoto
Takeshi Morimoto is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to improving patient outcomes, the organization collaborates with leading healthcare professionals and research institutions to design and implement rigorous clinical trials across various therapeutic areas. Emphasizing ethical standards and patient safety, Takeshi Morimoto leverages cutting-edge methodologies and data analytics to ensure robust trial execution and meaningful results. Their mission is to contribute significantly to the development of new therapies and enhance the understanding of disease management, ultimately benefiting both the medical community and patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kyoto, , Japan
Patients applied
Trial Officials
Takeshi Kimura, MD, PhD
Principal Investigator
Kyoto University, Graduate School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials